IVERIC bio (ISEE) Stock Price, News & Analysis

Company Overview

IVERIC bio, Inc., a biopharmaceutical company, focuses on the discovery and development of novel treatments for retinal diseases with unmet medical needs. The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; GATHER2 that is in Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD); and STAR or OPH2005 that is in Phase 2b clinical trial for the treatment of autosomal recessive Stargardt disease. Its preclinical product candidatures include IC-500, a high temperature requirement A serine peptidase 1 protein inhibitors for the treatment of GA and other age-related retinal diseases. The company also develops OPH2001 that has completed Phase 1/2a clinical trial of various doses of avacincaptad pegol (ACP) administered as a monotherapy for the treatment of GA; OPH2000, which has completed Phase 1/2a clinical trial of various doses of ACP administered in combination with Lucentis for the treatment of wet AMD; OPH2007 that has completed Phase 2a clinical trial for the treatment of wet AMD; and OPH2002, which has completed Phase 2a clinical trial for the treatment of idiopathic polypoidal choroidal vasculopathy. In addition, its minigene programs comprises miniCEP290 program for LCA10; miniABCA4 Program for STGD1; and miniUSH2A Program for usher syndrome type 2A-Related inherited retinal diseases (IRDs). The company was formerly known as Ophthotech Corporation and changed its name to IVERIC bio, Inc. in April 2019. The company was incorporated in 2007 and is based in Parsippany, New Jersey. As of July 11, 2023, IVERIC bio, Inc. operates as a subsidiary of Astellas US Holding, Inc.

Key Stats

• Today's Range: $39.95 to $39.95
• 50-Day Range: $36.90 to $39.95
• 52-Week Range: $9.39 to $39.99
• Volume: N/A
• Average Volume: 3.62 million shs
• Market Capitalization: $5.50 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ISEE Stock Analysis - Frequently Asked Questions

How were IVERIC bio's earnings last quarter?

IVERIC bio, Inc. (NASDAQ:ISEE) announced its quarterly earnings results on Wednesday, March, 1st. The company reported ($0.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by $0.10.
Read the conference call transcript.

What other stocks do shareholders of IVERIC bio own?

Based on aggregate information from My MarketBeat watchlists, some other companies that IVERIC bio investors own include Alibaba Group (BABA), Tesla (TSLA), Meta Platforms (META), NVIDIA (NVDA), Pfizer (PFE), Advanced Micro Devices (AMD) and CrowdStrike (CRWD).

Company Calendar

• Last Earnings: 3/01/2023
• Today: 7/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: NASDAQ:ISEE
• CIK: 1410939
• Web: ivericbio.com
• Phone: (609) 474-6755
• Fax: N/A
• Employees: 163
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($1.76)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$185.21 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -57.00%
• Return on Assets: -46.15%

Debt

• Debt-to-Equity Ratio: 0.20
• Current Ratio: 15.53
• Quick Ratio: 15.53

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.43 per share
• Price / Book: 9.02

Miscellaneous

• Outstanding Shares: 137,780,000
• Free Float: 134,063,000
• Market Cap: $5.50 billion
• Optionable: Optionable
• Beta: 1.06